statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Recap: Monopar Therapeutics Q4 Earnings

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Monopar Therapeutics reports Q4 EPS (12c) vs (22c) last year

WILMETTE, Ill., March 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer...

Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments

Monopar Therapeutics GAAP EPS of -$0.12...

Monopar Therapeutics GAAP EPS of -$0.12

InvestorPlace - Stock Market News, Stock Advice & Trading Tips
MNPR stock results show that Monopar Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.
The post...

MNPR Stock Earnings: Monopar Therapeutics Beats EPS for Q4 2023

Monopar Therapeutics Inc (MNPR) just unveiled an announcement. Monopar Therapeutics Inc. has recently shared a presentation on their latest radioph...

Monopar Therapeutics Unveils Radiopharma Advances Online

FIgure 1

 Biodistribution of Therapeutic Radioisotope Lu-177 Conjugated to MNPR-101 in Pancreatic Cancer (MIA PaCa-2) Tumor Xenograft

WILMETTE, Ill., March 05, 2024 (GLOBE...

Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program

WILMETTE, Ill., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer...

Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial

Figure 1

 Pancreatic Cancer (MIA-PaCa-2) Tumor Xenograft

 Figure 2.

 Tumor Efficacy Studies

WILMETTE, Ill., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Monopar...

Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers

WILMETTE, Ill., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer...

Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers

Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. It also focuses on building a drug development pipeline through the licensing, and acquisition of therapeutics in late preclinical and clinical development stages. The company was founded by Chandler Drew Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.

Volume	39,446.00
52-Wk High	$1.75
52-Wk Low	$0.2739

MNPR Monopar Therapeutics Inc

About

Feed

News

Sentiment

Fundamentals